<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00908622</url>
  </required_header>
  <id_info>
    <org_study_id>MIO/REG/PERCUTÁNEO</org_study_id>
    <nct_id>NCT00908622</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy of Percutaneous Implantation of Autologous Myoblasts in Patients With Old Infarction</brief_title>
  <acronym>PERCUTANEO</acronym>
  <official_title>Phase II, Blind, Controlled, Randomised Study of the Efficacy of Percutaneous Implantation of Autologous Myoblasts in Patients With Old Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Finabiotech</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is compare the improvement in global and regional cardiac function
      measured by echocardiography and magnetic resonance in patients with old myocardial
      infarction subject to cardiac catheterisation with percutaneous endocavity implantation of
      autologous myoblasts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ischaemic heart disease is one of the main causes of mortality and morbidity. In particular,
      myocardial infarction (MI) is of special significance, as the heart muscle cannot regenerate
      so a region's necrosis leads to the formation of a fibrous scar. In the last few years, new
      treatments have been developed for the acute phase of myocardial infarction.We have managed
      to slow down disease progression with these new treatments, but it continues to the
      development of end stage heart failure. This study tries to determine the benefit of cell
      cardiomyoplasty with autologous myoblasts in patients with old MI.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of enrollment
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ejection fraction and wall motion score index measured with M-mode and echocardiography</measure>
    <time_frame>12 months after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wall motion score index measured with echocardigraphy and magnetic resonance in the ITT population</measure>
    <time_frame>12 month after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viability measured with echocardigraphy and magnetic resonance in the ITT population</measure>
    <time_frame>12 month after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cardiac arrythmias in the ITT population</measure>
    <time_frame>12 month after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction measured with echocardiography in the ITT population</measure>
    <time_frame>12 month after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Old Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Skeletal myoblasts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous autologous myoblast implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No cells</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Percutaneous culture medium without cells implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous autologous myoblast implantation</intervention_name>
    <description>Endocavity implantation of autologous myoblasts</description>
    <arm_group_label>Skeletal myoblasts</arm_group_label>
    <other_name>Cellular therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac revascularization</intervention_name>
    <description>Cardiac revascularization</description>
    <arm_group_label>No cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnosis of myocardial infarction, absence of viability.

          -  Ejection fraction under 40% or 45% in symptomatic patients

          -  Aged from 30-80 years old.

          -  Negative pregnancy test (women of childbearing age)

          -  Informed consent granted

        Exclusion Criteria:

          -  Prior history of tachycardia or ventricular fibrillation (except in the acute phase of
             MI).

          -  Myocardial infarction with more than 10 years of evolution.

          -  Patients positive for HIV, HBV or HCB.

          -  Patients with organ dysfunction: liver and kidney function

          -  History of cancer or prior treatment with chemotherapy.

          -  The patient should not suffer from any concomitant severe and/or uncontrolled medical
             condition.

          -  Patients who, due to their geographical, psychiatric or social status, have
             difficulties in meeting the conditions established in the protocol.

          -  Pregnant or beast feeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe Prósper, MD, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Clínica Universidad de Navarra</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2009</study_first_submitted>
  <study_first_submitted_qc>May 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2009</study_first_posted>
  <last_update_submitted>September 10, 2015</last_update_submitted>
  <last_update_submitted_qc>September 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Percutaneous implantation of autologous myoblasts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

